2 assets in Behcet Disease

Therapeutic assets addressing Behcet Disease, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Bcma-Cd19 Ccar T Cells Behcet Disease	Peking University People's Hospital	P2	CCC (53)
Filgotinib Behcet Disease	UMC Utrecht	P2	CCC (53)